Pharmaceuticals
Regulatory Science

Rein Therapeutics enrolls first patients in Phase 2 IPF trial

Eight patients are now enrolled in the RENEW study of inhaled peptide LTI-03, with sites active in the US, Australia, and Poland.
Eight patients are now enrolled in the RENEW study of inhaled peptide LTI-03, with sites active in the US, Australia, and Poland.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Santhera proposes Dr Srishti Gupta for board ahead of May AGM

The Swiss rare-disease pharma is putting the former Idorsia CEO forward as an independent director at its 26 May annual general meeting.
The Swiss rare-disease pharma is putting the former Idorsia CEO forward as an independent director at its 26 May annual general meeting.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Medical Devices

Syncromune presents SYNC-T Phase 1 data at ECIO 2026

The Fort Lauderdale biotech reported an 87% overall response rate in a 15-patient Phase 1 study and is advancing to Phase 2 in metastatic
The Fort Lauderdale biotech reported an 87% overall response rate in a 15-patient Phase 1 study and is advancing to Phase 2 in metastatic
The Biotech Times Editorial Team  · 
Biotech

Tacalyx raises €11m to advance TACA-targeting ADC TCX-201 to clinic

The Berlin biotech selected TCX-201 as its first clinical candidate and targets a CTA filing in 2027 for gastrointestinal and solid tumours.
The Berlin biotech selected TCX-201 as its first clinical candidate and targets a CTA filing in 2027 for gastrointestinal and solid tumours.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Pharmaceuticals

Tempest Therapeutics to present TPST-2003 CAR-T data at ISCT 2026

Tempest will share updated REDEEM-1 Phase 1/2a results for its CD19/BCMA dual-targeting CAR-T in relapsed/refractory myeloma at Dublin's
Tempest will share updated REDEEM-1 Phase 1/2a results for its CD19/BCMA dual-targeting CAR-T in relapsed/refractory myeloma at Dublin's
The Biotech Times Editorial Team  · 
Pharmaceuticals

Teva Q1 2026: AUSTEDO hits $578m as brands offset generics slide

Teva posted $4.0bn in Q1 revenues as AUSTEDO, AJOVY and UZEDY collectively grew 41%, cushioning a sharp fall in lenalidomide generics.
Teva posted $4.0bn in Q1 revenues as AUSTEDO, AJOVY and UZEDY collectively grew 41%, cushioning a sharp fall in lenalidomide generics.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Teva to acquire Emalex Biosciences for up to $900m in neuroscience bet

Teva will pay $700m upfront for Emalex and its NDA-ready D1 receptor antagonist ecopipam, targeting paediatric Tourette syndrome.
Teva will pay $700m upfront for Emalex and its NDA-ready D1 receptor antagonist ecopipam, targeting paediatric Tourette syndrome.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Tonix Pharmaceuticals presents Phase 1 data for Lyme mAb TNX-4800

Tonix plans an adaptive Phase 2 field study of its anti-OspA monoclonal antibody in 2027, targeting a prevention gap with no approved U.S
Tonix plans an adaptive Phase 2 field study of its anti-OspA monoclonal antibody in 2027, targeting a prevention gap with no approved U.S
The Biotech Times Editorial Team  · 
Pharmaceuticals

Valneva closes €84m reserved offering to fund Lyme vaccine push

The Lyon-based vaccine specialist raised €37m at closing, with up to €47m more if warrants tied to FDA Lyme approval are exercised.
The Lyon-based vaccine specialist raised €37m at closing, with up to €47m more if warrants tied to FDA Lyme approval are exercised.
The Biotech Times Editorial Team  · 
Pharmaceuticals

Zealand Pharma and Roche to start petrelintide Phase 3 in H2 2026

The Copenhagen biotech and its Roche partner will advance their once-weekly amylin analog into Phase 3 obesity trials after Phase 2 showed double-digit
The Copenhagen biotech and its Roche partner will advance their once-weekly amylin analog into Phase 3 obesity trials after Phase 2 showed double-digit
The Biotech Times Editorial Team  · 
Digital Health

KFSH Named Saudi Arabia's Most Valuable Healthcare Brand

King Faisal Specialist Hospital and Research Centre (KFSH) has been named Saudi Arabia & the Middle East’s Most Valuable Healthcare Brand for the fourth consecutive year

King Faisal Specialist Hospital and Research Centre (KFSH) has been named Saudi Arabia and the Middle East’s Most Valuable Healthcare Brand for the fourth consecutive year, with its brand value surpassing USD 1.7 billion (SAR 6.3 billion), according to Brand Finance’s 2026 ran

The Biotech Times Editorial Team  · 
Cell & Gene Therapy

MW Does another test

its a long test to see what having a sponsored post looks like when publoshed.

A longer text on why we need this test adn what it looks like

Mark Walker  · 
Subscribe to